Video
Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC
Author(s):
Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer (mCRPC).
The multicenter, open-label, phase 1b trial tested the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in a wide variety of patient populations, says Agarwal. Based on encouraging efficacy and safety data, cohort 6, which consisted of patients with mCRPC, was expanded to a total of 130 patients. At this point, a large phase 3 trial had been planned.
The phase 3 trial will accrue patients all over the globe, including the United States. This study will further evaluate the combination of cabozantinib and atezolizumab in patients mCRPC, Agarwal concludes.
